<DOC>
	<DOCNO>NCT00236951</DOCNO>
	<brief_summary>To assess change hemoglobin level iron sucrose added regimen weekly , fixed dos erythropoietin patient respond erythropoietin therapy alone .</brief_summary>
	<brief_title>Intravenous ( IV ) Iron vs. No Iron Treatment Anemia Cancer Patients Undergoing Chemotherapy Erythropoietin Therapy</brief_title>
	<detailed_description>This two stage , randomize , control study cancer patient undergo plan undergo chemotherapy . After stage one , ( patient expose erythropoiesis stimulate agent ) , patient randomize receive either IV iron sucrose iron supplementation . Patients follow safety efficacy endpoint .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Histological Diagnosis Cancer Hgb &lt; /= 10 Ongoing Planned Chemotherapy Body Weight &gt; 50kg Free Active Infection Karnofsky Status 60 % 100 % Active infection Use Multivitamins iron within one week entry Myelophthisic bone marrow involvement tumor except hematologic malignancy Concurrent medical condition would prevent compliance jeopardize health patient Use IV iron product within two month study entry Blood Transfusions Hypoplastic bone marrow failure state Acute Leukemia Myeloproliferative syndrome Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>